Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01686061 · ClinicalTrials.gov registry record
Blepharospasm Patient Survey for Patients With Blepharospasm
A clinical trial, sponsored by Merz Pharmaceuticals.
- Completed
- Registry status
- 124
- Enrollment target
NCT01686061 is a clinical trial that has completed, run by Merz Pharmaceuticals. The registered enrollment target is 124 participants.
The verdict
NCT01686061 has completed, sponsored by Merz Pharmaceuticals.
- COMPLETED
- Registry status
- 124 participants
- Enrollment target
Study Summary
The purpose of this survey is to collect detailed information on patients treated for blepharospasm with incobotulinumtoxinA, abobotulinumtoxinA and onabotulinumtoxinA, including how often they are treated with botulinum toxin, how long their treatment lasts, how satisfied they are with their treatment, and if there is any improvement in their symptoms with the treatment.
Interventions
- OTHER No intervention- only one time survey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2012-09 |
| Est. Completion | 2013-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01686061
The ClinicalTrials.gov registry entry for NCT01686061 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merz Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which No intervention- only one time survey is the first listed.
NCT01686061 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01686061 about?
NCT01686061 is a clinical study titled "Blepharospasm Patient Survey for Patients With Blepharospasm". The purpose of this survey is to collect detailed information on patients treated for blepharospasm with incobotulinumtoxinA, abobotulinumtoxinA and onabotulinumtoxinA, including how often they are treated with botulinum toxin, how long their treatment lasts, how satisfied they are with their treatm...
What is the current status of trial NCT01686061?
This trial is currently completed. The enrollment target is 124 participants. The study started on 2012-09. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01686061?
The interventions under investigation include: No intervention- only one time survey (OTHER).
Who is sponsoring clinical trial NCT01686061?
This trial is sponsored by Merz Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.